Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 5 analysts that cover Supernus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $61.6, which forecasts a 28.98% increase in the stock price over the next year. The lowest target is $55 and the highest is $65.

Price Target: $61.6 (+28.98%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$55	$61.6	$63	$65
Change	+15.16%	+28.98%	+31.91%	+36.10%

* Price targets were last updated on Dec 19, 2025.

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	2	2	2	2	2	2
Buy	2	2	2	2	2	2
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Annabel Samimy Stifel	Stifel	Hold Maintains $50 → $55	Hold	Maintains	$50 → $55	+15.16%	Dec 19, 2025
Pavan Patel B of A Securities	B of A Securities	Strong Buy Initiates $65	Strong Buy	Initiates	$65	+36.10%	Oct 29, 2025
Stacy Ku TD Cowen	TD Cowen	Strong Buy Maintains $45 → $60	Strong Buy	Maintains	$45 → $60	+25.63%	Oct 23, 2025
David Amsellem Piper Sandler	Piper Sandler	Hold → Buy Upgrades $40 → $65	Hold → Buy	Upgrades	$40 → $65	+36.10%	Oct 9, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $46 → $63	Buy	Maintains	$46 → $63	+31.91%	Sep 30, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

885.71M

Increased by 23.19%

from 718.95M

Revenue Next Year

1.04B

Increased by 17.65%

from 885.71M

EPS This Year

1.96

from -0.68

EPS Next Year

4.88

Increased by 148.79%

from 1.96

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	579.78M	667.24M	607.52M	661.82M	718.95M	885.71M	1.04B
Revenue Growth	11.41%	15.09%	-8.95%	8.94%	8.63%	23.19%	17.65%
EPS	0.98	1.04	0.02	1.32	-0.68	1.96	4.88
EPS Growth	-58.48%	6.32%	-98.08%	6,500.00%	-	-	148.79%
Forward PE	-	-	-	-	-	24.35	9.79
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	931.1M	1.1B
Avg	885.7M	1.0B
Low	838.1M	947.0M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	29.5%	26.2%
Avg	23.2%	17.6%
Low	16.6%	6.9%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	2.78	9.00
Avg	1.96	4.88
Low	1.02	2.09

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	358.7%
Avg	-	148.8%
Low	-	6.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.